Clinical trial · Interventional
PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
Pilot Trial of PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn more about how a new study agent works inside the body. The study agent is a protein called 64Cu-trastuzumab. This is a radioactive tracer that was developed at MSKCC to target HER2 protein on cancer cells. A radioactive tracer is a small amount of radioactive dye that follows something else that is not radioactive In this study the study agent, 64Cu-trastuzumab, is the tracer and what's being followed is trastuzumab (Herceptin™). By giving you this tracer after you have treatment with trastuzumab (Herceptin™), we will be able to use PET scans to show us which parts of your body and tumor sites the Herceptin goes to. This will help us to understand better how Herceptin works in the body to fight cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET Imaging With Cu-64 Labeled Trastuzumab | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- breast cancer pt receiving trastuzumab therapy will undergo two complete PET studies.
- interventionNames
- Radiation: PET Imaging With Cu-64 Labeled Trastuzumab
- type
- EXPERIMENTAL
- label
- 2
- description
- breast cancer pt receiving trastuzumab therapy will undergo one complete PET studies
- interventionNames
- Radiation: PET Imaging With Cu-64 Labeled Trastuzumab
Primary outcomes (1)
- measure
- test safety & feas of (PET) imaging w radiolabeled 64Cu-trastuzumab to determine dosimetry & biodistribution of trastuzumab, using a radiotracer dilution technique w copper-64 labeled trastuzumab
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Registered patient at MSKCC * Age ≥18 years * Patients with HER2+ metastatic breast cancer (either 3+ by immunohistochemistry or with evidence of gene amplification (\>2.0) by fluorescence in situ hybridization (FISH)) * Measurable or evaluable disease * Currently taking or about to commence treatment with trastuzumab at a dosing schedule of 2 mg/kg weekly or 6 mg/kg every three weeks, as per standard of care * Karnofsky Performance Score ≥ 60 * Signed informed consent Exclusion Criteria: * Previous Grade 3 or higher allergic reaction to trastuzumab that resulted in discontinuation of trastuzumab therapy * Claustrophobia/pain leading to inability to lie still for the duration of the scanning procedure. * Pregnancy Test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material. * Inability to provide written informed consent. * Patients with liver metastases as the only site of distant disease * Patients with known sensitivity or contraindication to Herceptin.
References
Publications (0)
Data not yet available